Highlights
- LBM-based oxaliplatin dosing reduced grade ≥2 peripheral neurotoxicity compared to standard dosing.
- No compromise in relapse-free or overall survival when using LBM-adjusted doses.
- Quality of life was improved, and fewer dose reductions were needed in the LBM-based group.
